On September 11, 2023, Dianthus Therapeutics, Inc. closed the transaction. The company has received $71.987749 million private investment for the issuance of 2,873,988 common stock at a purchase price $23.34 per share for a gross proceeds $67.07888 million and 210,320 pre-funded warrants at a purchase price $23.34 per warrant for a gross proceeds of $4.908869 million in the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.92 USD | -2.79% | -2.79% | +110.77% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+110.77% | 634M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Dianthus Therapeutics, Inc. announced that it has received $71.987749 million in funding from a group of investors